Outstanding combination of efficacy and safety in the CONDUCT study
Read morePress releases
All releases
InDex Pharmaceuticals Holding AB (publ) interim report January – September 2019
27 November 2019
- Regulatory press release
InDex Pharmaceuticals presents at Redeye Life Science Day and Avanza Börsdag November 19, 2019
18 November 2019
- Other press release
November 18, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at...
Read moreInDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2020 Annual General Meeting
01 November 2019
- Other press release
November 1, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2020 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2020 Annual General Meeting proposals regarding election of the Chairman of t...
Read moreInDex Pharmaceuticals updates shareholders list
28 October 2019
- Other press release
October 28, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of October 18, 2019.
Read moreInDex Pharmaceuticals presents today at Redeye Investor After Work
24 October 2019
- Other press release
...
Read moreBulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)
09 October 2019
- Regulatory press release
October 9, 2019 – An Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) (“InDex” or the “Company”) took place on Wednesday, October 9, 2019 in the Company´s premises at Tomtebodavägen 23a in Stockholm, Sweden. At the Extraordinary General Meeting the following was resolve...
Read moreNotice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)
19 September 2019
- Regulatory press release
September 19, 2019 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to an Extraordinary General Meeting on Wednesday October 9, 2019 at 4:00 p.m. (CET) at the Company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at ...
Read moreInDex Pharmaceuticals has completed a directed share issue of approximately SEK 140 million (USD 14 million)
19 September 2019
- Regulatory press release
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE "UNITED STATES"), AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN,...
Read moreInDex Pharmaceuticals announces intention of a directed share issue
19 September 2019
- Regulatory press release
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA, THE "UNITED STATES"), AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN,...
Read moreInDex Pharmaceuticals updates shareholders list
05 September 2019
- Regulatory press release
September 5, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of August 30, 2019.
Read moreInDex Pharmaceuticals meets primary endpoint in the phase IIb study CONDUCT with cobitolimod in ulcerative colitis
27 August 2019
- Regulatory press release
· Outstanding combination of efficacy and safety · 15% delta vs. placebo for clinical remission August 27, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced positive top line results from the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of mod...
Read moreInDex Pharmaceuticals Holding AB (publ) interim report January – June 2019
15 August 2019
- Regulatory press release
Last patient enrolled in the CONDUCT study
Read moreInDex Pharmaceuticals gets new patent in Europe
26 June 2019
- Regulatory press release
June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the European Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic a...
Read moreInDex Pharmaceuticals enrolls last patient in phase IIb study CONDUCT with cobitolimod
26 June 2019
- Regulatory press release
June 26, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that patient enrolment was completed in the dose optimisation study CONDUCT, which is evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis. Top line results are expected to be available in 8...
Read moreInDex Pharmaceuticals presents at Redeye Growth Day on June 10, 2019
03 June 2019
- Other press release
...
Read moreInDex Pharmaceuticals presents at the Introduce Investor Days
23 May 2019
- Other press release
May 23, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at the Introduce Investor Days at Haymarket by Scandic in Stockholm on May 27 at 9.30 CET.
Read moreBulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
06 May 2019
- Regulatory press release
May 6, 2019 – The Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) took place on Monday, May 6, 2019 in the company´s premises at Tomtebodavägen 23a in Stockholm, Sweden.
Read moreInDex Pharmaceuticals Holding AB (publ) interim report January – March 2019
06 May 2019
- Regulatory press release
The final phase of the patient recruitment in the CONDUCT study
Read moreInDex Pharmaceuticals provides status update on the patient recruitment in the CONDUCT study
11 April 2019
- Regulatory press release
April 11, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that 197 patients, of the total 215 planned, have been enrolled to date in the CONDUCT study evaluating the drug candidate cobitolimod. The patient recruitment has varied significantly on a monthly basis, with between 6 and 19 p...
Read moreNotice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)
05 April 2019
- Regulatory press release
April 5, 2019 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820, are hereby summoned to the Annual General Meeting on Monday May 6, 2019 at 5:00 p.m. (CET) at the company´s premises, Tomtebodavägen 23a in Stockholm, Sweden. Registration for the meeting begins at 4:30 p.m.
Read moreInDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2018
02 April 2019
- Regulatory press release
April 2, 2019 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2018, which is earlier than indicated in the financial calendar. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, www.indexpharma.com.
Read moreInDex Pharmaceuticals Holding AB (publ) year end report 2018
20 February 2019
- Regulatory press release
Continued focus on the patient recruitment for the CONDUCT study
Read more